全文获取类型
收费全文 | 1481190篇 |
免费 | 103604篇 |
国内免费 | 2351篇 |
专业分类
耳鼻咽喉 | 21689篇 |
儿科学 | 50053篇 |
妇产科学 | 43817篇 |
基础医学 | 216730篇 |
口腔科学 | 40798篇 |
临床医学 | 123675篇 |
内科学 | 288068篇 |
皮肤病学 | 32305篇 |
神经病学 | 117540篇 |
特种医学 | 60104篇 |
外国民族医学 | 419篇 |
外科学 | 231137篇 |
综合类 | 28628篇 |
现状与发展 | 1篇 |
一般理论 | 358篇 |
预防医学 | 103083篇 |
眼科学 | 34666篇 |
药学 | 112339篇 |
1篇 | |
中国医学 | 3030篇 |
肿瘤学 | 78704篇 |
出版年
2018年 | 14536篇 |
2016年 | 13263篇 |
2015年 | 15172篇 |
2014年 | 19953篇 |
2013年 | 30029篇 |
2012年 | 41936篇 |
2011年 | 44007篇 |
2010年 | 26087篇 |
2009年 | 24243篇 |
2008年 | 43035篇 |
2007年 | 46691篇 |
2006年 | 47417篇 |
2005年 | 46981篇 |
2004年 | 45118篇 |
2003年 | 44036篇 |
2002年 | 43379篇 |
2001年 | 67053篇 |
2000年 | 68356篇 |
1999年 | 58101篇 |
1998年 | 16461篇 |
1997年 | 14838篇 |
1996年 | 14692篇 |
1995年 | 13777篇 |
1994年 | 13049篇 |
1993年 | 12153篇 |
1992年 | 45241篇 |
1991年 | 44469篇 |
1990年 | 43967篇 |
1989年 | 42531篇 |
1988年 | 39414篇 |
1987年 | 38638篇 |
1986年 | 36871篇 |
1985年 | 35134篇 |
1984年 | 26241篇 |
1983年 | 22621篇 |
1982年 | 13520篇 |
1981年 | 12042篇 |
1979年 | 24927篇 |
1978年 | 17571篇 |
1977年 | 15150篇 |
1976年 | 14206篇 |
1975年 | 15846篇 |
1974年 | 18401篇 |
1973年 | 17695篇 |
1972年 | 16849篇 |
1971年 | 15681篇 |
1970年 | 14514篇 |
1969年 | 13933篇 |
1968年 | 13150篇 |
1967年 | 11530篇 |
排序方式: 共有10000条查询结果,搜索用时 17 毫秒
121.
Jenny U. Johansson Nathaniel S. Woodling Qian Wang Maharshi Panchal Xibin Liang Angel Trueba-Saiz Holden D. Brown Siddhita D. Mhatre Taylor Loui Katrin I. Andreasson 《The Journal of clinical investigation》2015,125(1):350-364
Microglia, the innate immune cells of the CNS, perform critical inflammatory and noninflammatory functions that maintain normal neural function. For example, microglia clear misfolded proteins, elaborate trophic factors, and regulate and terminate toxic inflammation. In Alzheimer’s disease (AD), however, beneficial microglial functions become impaired, accelerating synaptic and neuronal loss. Better understanding of the molecular mechanisms that contribute to microglial dysfunction is an important objective for identifying potential strategies to delay progression to AD. The inflammatory cyclooxygenase/prostaglandin E2 (COX/PGE2) pathway has been implicated in preclinical AD development, both in human epidemiology studies and in transgenic rodent models of AD. Here, we evaluated murine models that recapitulate microglial responses to Aβ peptides and determined that microglia-specific deletion of the gene encoding the PGE2 receptor EP2 restores microglial chemotaxis and Aβ clearance, suppresses toxic inflammation, increases cytoprotective insulin-like growth factor 1 (IGF1) signaling, and prevents synaptic injury and memory deficits. Our findings indicate that EP2 signaling suppresses beneficial microglia functions that falter during AD development and suggest that inhibition of the COX/PGE2/EP2 immune pathway has potential as a strategy to restore healthy microglial function and prevent progression to AD. 相似文献
122.
Increased arterial stiffness in young normotensive patients with Turner syndrome: associations with vascular biomarkers
下载免费PDF全文
![点击此处可从《Clinical endocrinology》网站下载免费的PDF全文](/ch/ext_images/free.gif)
123.
A. Hochsprung S. Escudero-Uribe A.J. Ibáñez-Vera G. Izquierdo-Ayuso 《Neurología (Barcelona, Spain)》2021,36(6):433-439
IntroductionPain is highly prevalent in patients with multiple sclerosis (MS); it is chronic in 50% of cases and is classified as nociceptive, neuropathic, or mixed-type. Pain affects quality of life, sleep, and the activities of daily living. Electrotherapy is an interesting alternative or complementary treatment in the management of pain in MS, with new innovations constantly appearing.Material and methodsThis study evaluates the effectiveness of treatment with monopolar dielectric transmission of pulsed electromagnetic fields (PEMF) for pain associated with MS. We performed a randomised, placebo-controlled clinical trial including 24 patients, who were assessed with the Brief Pain Inventory, the Multiple Sclerosis International Quality of Life questionnaire, the Beck Depression Inventory, and the Modified Fatigue Impact Scale.ResultsStatistically significant improvements were observed in maximum and mean pain scores, as well as in the impact of pain on work, personal relationships, and sleep and rest. Not significant differences were found between the treatment and placebo groups.ConclusionsTreatment with PEMF may be effective in reducing pain in patients with MS, although further research is necessary to confirm its effectiveness over placebo and to differentiate which type of pain may be more susceptible to this treatment. 相似文献
124.
Clinical Spectrum of Capillary Malformation–Arteriovenous Malformation Syndrome Presenting to a Pediatric Dermatology Practice: A Retrospective Study
下载免费PDF全文
![点击此处可从《Pediatric dermatology》网站下载免费的PDF全文](/ch/ext_images/free.gif)
Nicole A. Weitz M.D. Christine T. Lauren M.D. Gerald G. Behr M.D. June K. Wu M.D. Jessica J. Kandel M.D. Philip M. Meyers M.D. Sally Sultan M.D. Kwame Anyane‐Yeboa M.D. Kimberly D. Morel M.D. Maria C. Garzon M.D. 《Pediatric dermatology》2015,32(1):76-84
Capillary malformation–arteriovenous malformation syndrome (CM‐AVM) is an autosomal dominant disorder caused by RASA1 mutations. The prevalence and phenotypic spectrum are unknown. Evaluation of patients with multiple CMs is challenging because associated AVMs can be life threatening. The objective of this study was to describe the clinical characteristics of children presenting with features of CM‐AVM to an academic pediatric dermatology practice. After institutional review board approval was received, a retrospective chart review was performed of patients presenting between 2009 and 2012 with features of CM‐AVM. We report nine cases. Presenting symptoms ranged from extensive vascular stains and cardiac failure to CMs noted incidentally during routine skin examination. All demonstrated multiple CMs, two had Parkes Weber syndrome, and two had multiple infantile hemangiomas. Seven patients had family histories of multiple CMs; three had family histories of large, atypical CMs. Six had personal or family histories of AVMs. Genetic evaluation was recommended for all and was pursued by six families; four RASA1 mutations were identified, including one de novo. Consultations with neurology, cardiology, and orthopedics were recommended. Most patients (89%) have not required treatment to date. CM‐AVM is an underrecognized condition with a wide clinical spectrum that often presents in childhood. Further evaluation may be indicated in patients with multiple CMs. This study is limited by its small and retrospective nature. 相似文献
125.
126.
127.
128.
129.